A critical appraisal of the ATLAS trial of maintenance therapy for multiple myeloma: end points, censoring and equipoise
Crossref DOI link: https://doi.org/10.1038/s41571-023-00801-x
Published Online: 2023-07-11
Published Print: 2023-11
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Mohyuddin, Ghulam Rehman
Meirson, Tomer
Text and Data Mining valid from 2023-07-11
Version of Record valid from 2023-07-11
Article History
First Online: 11 July 2023
Competing interests
: T.M. reports receiving personal fees from Purple Biotech, outside the submitted work. G.R.M. declares no competing interests